MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy

Santiago Montes-Moreno, Nerea Martinez, Beatriz Sanchez-Espiridión, Ramon Díaz Uriarte, Maria Elena Rodriguez, Anabel Saez, Carlos Montalbán, Gonzalo Gomez, David G. Pisano, Juan Fernando García, Eulogio Conde, Eva Gonzalez-Barca, Andres Lopez, Manuela Mollejo, Carlos Grande, Miguel Angel Martinez, Cherie Dunphy, Eric D. Hsi, Gabrielle B. Rocque, Julie ChangRonald S. Go, Carlo Visco, Zijun Xu-Monette, Ken H. Young, Miguel A. Piris

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Diffuse large B-cell lymphoma (DLBCL) prognostication requires additional biologic markers. miRNAs may constitute markers for cancer diagnosis, outcome, or therapy response. In the present study, we analyzed the miRNA expression profile in a retrospective multicenter series of 258 DLBCL patients uniformly treated with chemoimmunotherapy. Findings were correlated with overall survival (OS) and progression-free survival (PFS). miRNAand gene-expression profiles were studied using microarrays in an initial set of 36 cases. A selection of miRNAs associated with either DLBCL molecular subtypes (GCB/ABC) or clinical outcome were studied by multiplex RT-PCR in a test group of 240 cases with available formalinfixed, paraffin-embedded (FFPE) diagnostic samples. The samples were divided into a training set (123 patients) and used to derive miRNA-based and combined (with IPI score) Cox regression models in an independent validation series (117 patients). Our model based on miRNA expression predicts OS and PFS and improves upon the predictions based on clinical variables. Combined models with IPI score identified a high-risk group of patients with a 2-yearOSand aPFSprobability of < 50%. In summary, a precise miRNA signature is associated with poor clinical outcome in chemoimmunotherapy-treated DLBCL patients. This information improves upon IPI-based predictions and identifies a subgroup of candidate patients for alternative therapeutic regimens.

Original languageEnglish (US)
Pages (from-to)1034-1040
Number of pages7
JournalBlood
Volume118
Issue number4
DOIs
StatePublished - Jul 28 2011

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Montes-Moreno, S., Martinez, N., Sanchez-Espiridión, B., Uriarte, R. D., Rodriguez, M. E., Saez, A., Montalbán, C., Gomez, G., Pisano, D. G., García, J. F., Conde, E., Gonzalez-Barca, E., Lopez, A., Mollejo, M., Grande, C., Martinez, M. A., Dunphy, C., Hsi, E. D., Rocque, G. B., ... Piris, M. A. (2011). MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood, 118(4), 1034-1040. https://doi.org/10.1182/blood-2010-11-321554